Medtronic Faces $88 Million Verdict in Hernia Mesh Trial
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowMedtronic has been ordered to pay $88 million in a verdict related to a hernia mesh trial. The jury found that the company was liable for damages due to complications linked to its product. This verdict comes amidst ongoing litigation concerning the safety and effectiveness of Medtronic's hernia mesh devices. Such legal outcomes can impact Medtronic's (MDT) reputation and financial performance, influencing investor sentiment and market confidence.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Medtronic plc (MDT)
Medtronic is one of the world’s largest medical-device makers.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier MDT news
- Medtronic (MDT) Reports Highest Annual Revenue Growth in Decade
- Medtronic (MDT) Tariff Impact Reduces Estimates to $250 Million
- Medtronic (MDT) Reports Strong Q4 with $36 Billion Revenue Growth
- Medtronic (MDT) Gains FDA Approval for New Robotic Surgery Platform
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
